BRANT ADOMIAK: Open Payments
NPI 1689953937 · WILKES BARRE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,875 in 83 payments from 17 companies in 2025. Trend: 2023 $339 · 2024 $1,489 · 2025 $1,875
Food & beverage: $1,875
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 24 | $707 |
| GlaxoSmithKline, LLC. | 13 | $276 |
| Grifols USA, LLC | 6 | $208 |
| Verona Pharma, Inc. | 12 | $183 |
| Philips North America LLC | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 5 | $75 |
| Insmed, Inc. | 4 | $69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $61 |
| Vifor Pharma, Inc. | 2 | $54 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
Products named: FASENRA, Prolastin-C Liquid, Ohtuvayre, NUCALA, DUPIXENT, TRELEGY ELLIPTA, AIRSUPRA, Vest Therapy Und.
Industry payments across PA — which companies pay providers there.
